Matinas BioPharma FY26 Q2 net loss narrows to $3.25 million
MTNB•Six-month loss narrows and costs decline
- Matinas BioPharma narrowed its net loss to USD 3.25 million for the six months ended June 30, 2026.
- General and administrative expense dipped 5.62% to USD 3.49 million, driven by lower headcount and lease costs.
- Net cash used in operating activities eased to USD 3.44 million; cash and cash equivalents totaled USD 761,000 at June 30.
Business combination and asset sale agreements
- Matinas BioPharma entered a business combination agreement with GH Power and expects GH Power's business to become the combined company's primary focus.
- It also signed a stock sale agreement with Azurity for Nanotechnologies, with up to USD 21.5 million in consideration and a mid-single-digit royalty on MAT2203.
